PATENT CLAIM ANALYSIS

Application Number: 16083865
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["424", "637000"]

Abstract:
An ophthalmic composition or dosage form can include a therapeutically effective amount of a cross-linking agent and a pharmaceutically acceptable carrier. The composition or dosage form can be used to treat an ophthalmic condition by administering a therapeutically effective amount of the composition to an eye of a subject during a treatment period.

Claim (Index 17):
The method of  claim 16 , wherein the ophthalmic condition comprises at least one of keratoconus, peripheral ulcerative keratitis, corneal ulcers, corneal melts, pellucid marginal degeneration, Terrien's marginal degeneration, neurotrophic disease of the cornea, and corneal ectasia.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 97.0
- Lexical Diversity: 1.57143
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13665495', '13387668', '13480127', '15570016', '12315829']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.71846840291903
- 35 USC 102 Novelty (BERT): 0.4982692216650329
- Combined Prediction Score: 0.6964484847936303
- Mean Citation Score: 180.467596
- Max Citation Score: 190.64987
- Similarity Product: 119.43275920671223

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test